Bevacizumab
- Generic Name
- Bevacizumab
- Brand Names
- Avastin, Mvasi, Oyavas, Alymsys, Aybintio, Abevmy, Vegzelma, Onbevzi, Zirabev, Lytenava, Avzivi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 216974-75-3
- Unique Ingredient Identifier
- 2S9ZZM9Q9V
- Background
There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells. VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies.
...
- Indication
As a vascular endothelial growth factor (VEGF) inhibitor, bevacizumab is used in several chemotherapy regimens to treat metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer;...
- Associated Conditions
- Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Colorectal Cancer (CRC), Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Persistent Cervical Cancer, Recurrent Cervical Cancer, Recurrent Glioblastoma, Relapsed Glioblastoma, Stage III Fallopian Tube Cancer, Stage III Ovarian Epithelial Cancer, Stage III Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer, Recurrent Platinum-Sensitive Epithelial Ovarian Cancer, Recurrent Platinum-resistant Epithelial Ovarian Cancer, Recurrent platinum drug resistant Fallopian tube cancer, Recurrent platinum drug resistant primary peritoneal cancer, Recurrent platinum sensitive primary peritoneal cancer, Recurrent platinum-sensitive fallopian tube cancer, Unresectable Non-Squamous Non-Small Cell Lung Cancer, Unresectable, advanced Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
- Associated Therapies
- First Line Chemotherapy, First or Second Line Therapy, Second Line Treatment
Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-05-11
- Last Posted Date
- 2016-01-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 37
- Registration Number
- NCT00324870
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Peninsula Oncology and Hematology PA, Salisbury, Maryland, United States
🇺🇸University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-05-10
- Last Posted Date
- 2016-09-07
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 48
- Registration Number
- NCT00323869
- Locations
- 🇺🇸
Santa Clara Valley Medical Center, San Jose, California, United States
🇺🇸VA Palo Alto Healthcare System, Palo Alto, California, United States
🇺🇸Stanford University School of Medicine, Stanford, California, United States
Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma
- First Posted Date
- 2006-05-09
- Last Posted Date
- 2013-07-26
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 80
- Registration Number
- NCT00323739
- Locations
- 🇺🇸
Baton Rouge General Medical Center, Baton Rouge, Louisiana, United States
🇺🇸Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸Wellstar Cancer Research, Marietta, Georgia, United States
Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy
- Conditions
- Interventions
- First Posted Date
- 2006-05-04
- Last Posted Date
- 2016-05-16
- Lead Sponsor
- Mary-Ellen Taplin, MD
- Target Recruit Count
- 42
- Registration Number
- NCT00321646
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2013-07-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 187
- Registration Number
- NCT00320541
- Locations
- 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico
Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab
- Conditions
- Interventions
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT00321100
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Safety Study of Bevacizumab to Treat Women With a History of Breast Cancer and Suffering From Upper Extremity Lymphedema
- Conditions
- First Posted Date
- 2006-04-26
- Last Posted Date
- 2006-05-10
- Lead Sponsor
- Premiere Oncology of Arizona
- Target Recruit Count
- 35
- Registration Number
- NCT00318513
- Locations
- 🇺🇸
Premiere Oncology of Arizona, Scottsdale, Arizona, United States
A Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer (BRIDGE)
- Conditions
- Interventions
- First Posted Date
- 2006-04-26
- Last Posted Date
- 2010-05-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT00318136
A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer
- First Posted Date
- 2006-04-24
- Last Posted Date
- 2011-05-02
- Lead Sponsor
- Hoosier Cancer Research Network
- Target Recruit Count
- 34
- Registration Number
- NCT00317200
- Locations
- 🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States
🇺🇸Cancer Care Center of Southern Indiana, Bloomington, Indiana, United States
Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon
- Conditions
- Interventions
- First Posted Date
- 2006-04-13
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 7
- Registration Number
- NCT00314353
- Locations
- 🇺🇸
NSABP Operations Center, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.